Spyre Earnings Reports

Spyre Therapeutics reported $603.1 million in cash, cash equivalents, and marketable securities as of December 31, 2024. Net loss for the quarter was $56.3 million. The company highlighted positive interim Phase 1 results for SPY001 and advancements in its pipeline, including planned Phase 2 trials in ulcerative colitis and rheumatoid arthritis.

Spyre Therapeutics reported a net loss of $69.0 million for the third quarter of 2024. The company's cash, cash equivalents, and marketable securities totaled $414.2 million as of September 30, 2024, expected to fund operations well into 2027.

Spyre Therapeutics reported a net loss of $38.8 million for the second quarter of 2024. The company's cash and cash equivalents, marketable securities, and restricted cash totaled $426.3 million as of June 30, 2024. Dosing was initiated in the Phase 1 trial of SPY001, with interim proof-of-concept data expected by year-end 2024.

Spyre Therapeutics reported a net loss of $43.9 million for the first quarter of 2024. The company's cash position was $485.0 million as of March 31, 2024, providing a cash runway well into 2027. SPY001 is on track to begin first-in-human studies in the second quarter of 2024 and SPY002 remains on track to begin first-in-human studies in the second half of 2024.

Spyre Therapeutics announced its fourth quarter and full year 2023 financial results, highlighting the advancement of its IBD therapies and a strong cash position of $339.6 million. The company is progressing with clinical studies across multiple programs and anticipates Phase 2 evaluation of rational therapeutic combinations in IBD patients in 2025.

Aeglea BioTherapeutics reported a net loss of $40.1 million for the third quarter of 2023, with R&D expenses totaling $24.7 million and G&A expenses totaling $8.6 million. The company's cash and cash equivalents, marketable securities, and restricted cash totaled $204.9 million as of September 30, 2023.

Aeglea BioTherapeutics reported second quarter 2023 financial results, including $236.7 million in cash and cash equivalents, $0.7 million in revenue, and a net loss of $217.1 million. The company completed the acquisition of Spyre Therapeutics, raised $210.0 million in gross proceeds, and sold global rights to pegzilarginase for $15.0 million upfront and up to $100.0 million in contingent milestone payments.

Aeglea BioTherapeutics reported a net loss of $18.4 million and revenue of $0.2 million for the first quarter of 2023. The company had $39.8 million in cash and cash equivalents, marketable securities, and restricted cash as of March 31, 2023.

Aeglea BioTherapeutics reported Q4 2022 financial results, including development fee revenues of $0.2 million and a net loss of $18.8 million. The company's cash, cash equivalents, marketable securities, and restricted cash totaled $57.3 million as of December 31, 2022, expected to fund operations into Q4 2023.

Aeglea BioTherapeutics reported $75.2 million in cash as of September 30, 2022. The company recognized development fee revenues of $0.2 million in the third quarter of 2022. Research and development expenses totaled $12.0 million and general and administrative expenses totaled $7.0 million for the third quarter of 2022. Net loss totaled $18.2 million for the third quarter of 2022.